Enabling High-Throughput Biology With New Technologies for Synthetic Construct Sequencing

Octant is a therapeutics company building a platform to navigate the complexity of biology and chemistry to create the next generation of small molecules. In this video, Octant’s Henry Chan, PhD, and Bryan Jiang discuss their collaboration with seqWell, which helped them develop and improve OCTOPUS – a high-throughput construct sequencing platform that they’ve used to enable their drug discovery efforts.